BV Investment Partners Announces Majority Investment in The Millennium Alliance   Read More
Prev
Next

Overview

With consumer demands evolving at a rapid pace in today’s innovation economy, we have decided to gather a select group of 10-15 top technology leaders from forward-thinking brands to participate in open-format discussions about the current trends and evolving challenges the industry is facing.

Overview Location Image

Blackbarn

New York City

Go to Website
Objectives
icon
STRATEGICALLY CURATING

like-minded leaders in a relaxed but focused manner

icon
CREATING AN ENVIRONMENT

conducive for you to establish powerful connections

icon
IDENTIFYING NEW OPPORTUNITIES

to ensure your brand sustains its competitive advantage

roundable Discussions Image

Roundtable Discussions

During the Dinner you will participate in an interactive roundtable discussion of your choosing. Below are the topics:

  • Where do the real R&D gains from AI lie—cutting headcount, increasing throughput, or de-risking bets?
  • Smarter Bets: Is agentic AI the Next R&D Hypothesis Engine?
  • Transforming Tomorrow: A Roundtable on Gen AI in Life Sciences R&D

Dinner Format

  • Cocktail Hour
  • Welcome Address
  • Dinner and Roundtable Discussions
  • Dessert & Round-robin
image dinner
Learn More

About Causaly

Founded in 2018 and backed by $93 million from ICONIQ Growth, Index Ventures, and other top-tier investors, Causaly is the only platform that combines agentic AI, a high-precision knowledge graph, and frictionless adoption, enabling life sciences organizations to reduce risk and increase R&D productivity at scale. Its enterprise-ready platform, Causaly Cloud—the first production-grade generative AI platform for research and workflow automation—synthesizes vast amounts of unstructured and proprietary data into transparent, evidence-linked answers and insights, streamlining hypothesis generation and accelerating decision-making. Thousands of researchers at the world’s leading pharmaceutical organizations use Causaly daily—from target and biomarker discovery to horizon scanning and competitive intelligence analysis—redeploying time saved from manual data reviews into better informed and designed experiments that drive more successful preclinical and clinical programs. Causaly customers have reported up to 10× faster evidence synthesis and measurable ROI through accelerated decision cycles and reduced program risk.

For more information, visit www.causaly.com

About Causaly

Founded in 2018 and backed by $93 million from ICONIQ Growth, Index Ventures, and other top-tier investors, Causaly is the only platform that combines agentic AI, a high-precision knowledge graph, and frictionless adoption, enabling life sciences organizations to reduce risk and increase R&D productivity at scale. Its enterprise-ready platform, Causaly Cloud—the first production-grade generative AI platform for research and workflow automation—synthesizes vast amounts of unstructured and proprietary data into transparent, evidence-linked answers and insights, streamlining hypothesis generation and accelerating decision-making. Thousands of researchers at the world’s leading pharmaceutical organizations use Causaly daily—from target and biomarker discovery to horizon scanning and competitive intelligence analysis—redeploying time saved from manual data reviews into better informed and designed experiments that drive more successful preclinical and clinical programs. Causaly customers have reported up to 10× faster evidence synthesis and measurable ROI through accelerated decision cycles and reduced program risk.

For more information, visit www.causaly.com